¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Spinner (New Bedford, Mass.)"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • equivalent mass
    µî°¡Áú·®
  • fat-free body mass
    Áö¹æÁ¦¿ÜüÁß
  • gravitational mass
    Áß·ÂÁú·®
  • inner cell mass
    ¼Ó¼¼Æ÷µ¢ÀÌ, ³»¼¼Æ÷±«
  • intermediate cell mass
    Áß°£¼¼Æ÷µ¢ÀÌ, Áß°£¼¼Æ÷±«
  • lateral mass
    °¡Âʵ¢ÀÌ
  • lean body mass
    Áö¹æ»«Ã¼Áß, ¸¶¸¥Ã¼Áß
  • mass
    1. µ¢ÀÌ, Á¾±« 2. Áý´Ü 3. Áú·®
  • mass action
    Áú·®ÀÛ¿ë
  • mass attenuation coefficient
    Áú·®°¨¼è°è¼ö
  • mass casualty incident
    ´ëÇüÀç³­»ç°í
  • mass chemotherapy
    Áý´ÜÈ­Çпä¹ý
  • mass consumption
    ´ë·®¼Òºñ
  • mass contraction
    Áý´Ü¼öÃà
  • mass effect
    µ¢ÀÌÈ¿°ú, Á¾±«È¿°ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mass consumption
    ´ë·®¼Òºñ
  • mass contraction
    Áý´Ü¼öÃà
  • mass attenuation coefficient
    Áú·®°¨¼è°è¼ö
  • mass energy absorption coefficient
    Áú·®¿¡³ÊÁöÈí¼ö°è¼ö
  • mass energy transfer coefficient
    Áú·®¿¡³ÊÁöÀüÀ̰è¼ö
  • selective mass chemotherapy
    ¾ç¼ºÀÚÁý´ÜÄ¡·á, ¾ç¼ºÀÚÁý´ÜÄ¡·á
  • mass disaster
    ´ëÇü»ç°í, Âü»ç
  • echogenic mass
    ¸Þ¾Æ¸®¹ß»ýµ¢ÀÌ, ¿¡Äڹ߻ýµ¢ÀÌ
  • effective mass
    À¯È¿Áú·®
  • electronic mass
    ÀüÀÚÁú·®
  • embryonic mass
    ¹è¾Æµ¢ÀÌ
  • equivalent mass
    µî°¡Áú·®
  • mass effect
    µ¢ÀÌÈ¿°ú
  • mass epidemic
    Áý´ÜÀ¯Çà
  • mass examination
    Áý´Ü°ËÁø, Áý´Ü°Ë»ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • body-mass index
    ½ÅüÁú·®Áö¼ö(ãóô÷òõÕáò¦â¦)
  • cardiac mass
    ½ÉÀåÁ¾·ù(ãýíôðþ×»),Á¾±«(ðþÎÔ)
  • cavitated mass
    °øµ¿¼º Á¾±«
  • cell mass
    ¼¼Æ÷µ¢¾î¸®, ¼¼Æ÷±«
  • cell mass
    ¿ø±â¼¼Æ÷±º(ê«Ðñá¬øàÏØ).
  • charge-to mass ratio
    ÀüÇÏ´ëÁú·®ºñ
  • cheesy mass
    °Ç¶ô¼º Á¾±«
  • congenital neck mass
    ¼±Ãµ(¼º) °æºÎÁ¾±«
  • dorsal mass
    µîÂʵ¢ÀÌ
  • echogenic mass
    ¿¡ÄÚ ¹ß»ý Á¾±«
  • effective mass
    À¯È¿Áú·®.
  • electronic mass
    ÀüÀÚÁú·®.
  • embryonic mass
    ¹èÀÚµ¢ÀÌ
  • equivalent mass
    µî°¡Áú·®
  • gravitational mass
    Áß·ÂÁú·®(ñìÕôòõÕá).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mass fragmentography
    Áú·®(òõÕá) ÇÁ·¡±×¸àÅä±×·¡ÇÇ
  • mass number
    Áú·®¼ö(òõÕáâ¦)
  • mass spectrogram
    Áú·®ºÐ±¤µµ(òõÕáÝÂÎÃÓñ)
  • mass spectrograph
    Áú·®ºÐ±¤±â(òõÕáÝÂÎÃѦ)
  • mass spectrometer
    Áú·®ºÐ±¤°è(òõÕáÝÂÎÃͪ)
  • mass spectrum
    Áú·®(òõÕá) ½ºÆåÆ®·³
  • mass unit
    Áú·®´ÜÀ§(òõÕáÓ¤êÈ)
  • molar mass
    ¸ô Áú·®(òõÕá)
  • molecular mass
    ºÐÀÚÁú·®(ÝÂí­òõÕá)
  • nuclidic mass
    ´©Å¬¶óÀ̵å Áú·®(òõÕá)
  • quadrupole mass spectrometer
    »çÁß±ØÀÚ(ÞÌñìпí­) Áú·®ºÐ±¤°è(òõÕáÝÂÎÃͪ).
  • secondary ion mass spectrometry
    ÀÌÂ÷ ÀÌ¿ÂÁú·®ºÐ±¤¹ý(ì£ó­òõÕáÝÂÎÃÛö)
  • tandem mass spectrometry
    Á÷¿­ Áú·® ºÐ¼®¹ý (òÁæêòõÕáÝÂà°Ûö)
  • unit mass
    ´ÜÀ§(Ó¤êÈ) Áú·®(òõÕá)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • polypoid mass
    Æú¸³¾çÁ¾±«
  • sonolucent mass
    ÃÊÀ½ÆÄÅõ°ú¼ºÁ¾±«
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TTNB Transient Tachypnea of New Born
ANDA Abbreviated New Drug Application
IND indomethacin; industrial medicine; investigational new drug
NAD neutrophil actin dysfunction; new antigenic determinant; nicotinamide adenine dinucleotide; nicotini...
NADA New Animal Drug Application
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NACI New Approaches to Coronary Intervention
NDA New Drug Application
NEJM New England Journal of Medicine
NSW New South Wales
NY New York
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • mass increase
    ÀÀ¾î¸® Áõ°¡
  • mass lesion
    Á¾±«¼º º´º¯
  • mass miniature radiography
    Áý´Ü Ãà¼Ò ¹æ»ç¼± ÃÔ¿µ¼ú, Áý´Ü °£Á¢ ÃÔ¿µ¼ú
  • mass movement
    Áý´Ü ¿îµ¿
  • mass peristalsis
    Áý´Ü ¿¬µ¿, ´ë·® À̵¿¼º ¿¬µ¿
  • mass radiography apparatus
    Áý´Ü ¹æ»ç¼± ÃÔ¿µ ÀåÄ¡
  • mass spectrography
    Áú·® ºÐ±¤ °èÃø¹ý
  • mass susceptibility
    Áú·® ¹Î°¨µµ
  • mobile mass radiography stand
    À̵¿Çü Áý´Ü ¹æ»ç¼± ÃÔ¿µ´ë
  • polypoid mass
    Æú¸³¾ç Á¾±«
  • protruding lateral mass
    µ¹Ãâ Ãø¸é
  • sonolucent mass
    ÃÊÀ½ÆÄ Åõ°ú¼º Á¾±«
  • tissue mass
    Á¶Á÷ µ¢¾î¸®
  • tumor mass
    Á¾¾ç
  • virtual mass
    °¡»ó Áú·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
new mutation Redundant term for a heritable trait present in the offspring but in neither parent, i.e., not a pre-existing mutant form inherited.
(05 Mar 2000)
new south wales A state in southeastern Australia. Its capital is sydney. It was discovered by captain cook in 1770 and first settled at botany bay by marines and convicts in 1788. It was named by captain cook who thought its coastline resembled that of south wales.
(12 Dec 1998)
New World leishmaniasis A grave disease caused by Leishmania braziliensis braziliensis, endemic in southern Mexico and Central and South America, except for the equatorial region of Chile; the organism does not invade the viscera, and the disease is limited to the skin and mucous membranes, the lesions resembling the sores of cutaneous leishmaniasis caused by L. Mexicana or L. Tropica; the chancrous sores heal after a time, but some months or years later, fungating and eroding forms of ulceration may appear on the tongue and buccal or nasal mucosa; many variants of the disease exist, marked by differences in distribution, vector, epidemiology, and pathology, which suggest that it may in fact be caused by a number of closely related aetiological agents.
See: espundia.
Synonym: American leishmaniasis, leishmaniasis americana, nasopharyngeal leishmaniasis, New World leishmaniasis.
(05 Mar 2000)
new yellow enzyme The d-amino-acid oxidase found in yeast, a flavoenzyme, which contains FAD as coenzyme instead of FMN as does NADPH dehydrogenase; so-called to distinguish it from Warburg's old yellow enzyme.
Compare: amino acid oxidases.
(05 Mar 2000)
New York Heart Association classification A functional classification to assess cardiovascular disability. Class I: patients with cardiac disease without limitation of physical activity. Ordinary activity does not cause symptoms. Class II: patients with cardiac disease with slight limitation of activity; comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or angina. Class III: patients with cardiac disease producing marked limitation of activity: comfortable at rest. Less than ordinary physical activity causes symptoms. Class IV: patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms may be present even at rest.
(05 Mar 2000)
new zealand A group of islands in the South Pacific Ocean. New Zealand flax.
<botany> A myrtaceous shrub (Leptospermum scoparium) of new Zealand and Australia, the leaves of which are used as a substitute for tea.
Source: Websters Dictionary
(01 Mar 1998)
New Zealand mice Inbred strains of mice, either black (NZB) or white (NZW), unique among strains used in experimental immunology because of their proclivity to spontaneous immunologic abnormalities and disorders including systemic lupus erythematosus similar to that found in humans.
(05 Mar 2000)
investigational new drug Status given an experimental drug after the FDA approves an application for testing it in people.
(09 Oct 1997)
investigational new drug application An application that must be submitted to a regulatory agency (the FDA in the united states) before a drug can be studied in humans. This application includes results of previous experiments; how, where, and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in animal studies; and how the compound is manufactured.
(12 Dec 1998)
adrenal mass <radiology> Metastasis, most common (especially lung, melanoma), primary adenocarcinoma, large at diagnosis (greater than 5 cm), usually functional (increased corticosteroids most likely to be Cushing's), rapid growth, benign adrenal adenoma, with or without functional, nonfunctional occurs in 2-8% of population, diff from metastasis: MRI (metastasis bright on T2), biopsy, follow, pheochromocytoma, neuroblastoma, myelolipoma, cyst / pseudocyst see also: adrenal calcification, haemorrhage
(12 Dec 1998)
apperceptive mass The already existing knowledge base in a similar or related area with which the new perceptual material is articulated.
(05 Mar 2000)
atomic mass <chemistry, physics> The mass of an atom relative to other atoms.
The present-day basis of the scale of atomic weights is carbon, the most common isotope of this element has arbitrarily been assigned an atomic weight of 12.
The unit of the scale is 1/12 the weight of the carbon atom or roughly the mass of one proton or one neutron. The atomic weight of any element is approximately equal to the total number of protons and neutrons in is nucleus
(16 Dec 1997)
atomic mass unit <chemistry> One-twelfth the mass of a neutral atom of the most abundant isotope of carbon.
(16 Dec 1997)
bilateral adrenal mass <radiology> Acute granulomatous disease (e.g., TB), metastases (bilateral in 15%), pheochromocytoma (bilateral in 10%), adrenal hyperplasia (adenoma), spontaneous adrenal haemorrhage
(12 Dec 1998)
body mass index One of the anthropometric measures of body mass; it has the highest correlation with skinfold thickness or body density.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mass
    ¹Ì»ç(Ä«Å縯±³ÀÇ ¼ºÃ¼ ¼º»ç);¹Ì»ç°î High Mass (ºÐÇâ,ÁÖ¾ÇÀÌ ÀÖ´Â) ´ë¹Ì»ç
  • mass
    ÇÑ µ¢¾î¸®·Î ÇÏ´Ù(µÇ´Ù);ÁýÁß½ÃŰ´Ù(ÇÏ´Ù)
  • mass action
    Áú·® ÀÛ¿ë
  • mass behavior
    ´ëÁß Çൿ
  • mass circulation
    (´ë·® ¹ßÇàÇÏ´Â) ÀÏ¹Ý ´ëÁß ÀâÁö
  • mass communication
    ´ëÁß Àü´Þ;¸Å½ºÄ¿¹Â´ÏÄÉÀ̼Ç
  • mass defect
    Áú·® °á¼Õ
  • mass driver
    ¿ìÁÖ ±âÀç ¹ß»ç ÀåÄ¡
  • mass energy
    Áú·® ¿¡³ÊÁö
  • mass game
    Áý´Ü °æ±â
  • mass grave
    °øµ¿ ¹¦Áö (µ¿½Ã¿¡ ¸ÅÀåµÈ ¸¹Àº »ç¶÷µéÀÇ ¹¦Áö)
  • mass leave
    (Àεµ¿¡¼­ Ç×ÀÇÇϱâ À§ÇØ ¸¹Àº Á¾¾÷¿øÀÌ ÇÏ´Â) ÀÏÁ¦ ÈÞ°¡
  • mass man
    ´ëÁßÀû(Áý´Ü) Àΰ£ (´ëÁß »çȸ¸¦ ±¸¼ºÇÏ´Â °¡Á¤µÈ ÀüÇüÀû Àΰ£À¸·Î,°³¼ºÀÌ »ó½ÇµÊ)
  • mass media
    ´ëÁß Àü´Þ ±â°ü (¹æ¼Û,½Å¹®µî) (sing,mass medium)
  • mass medication
    (»ó¼öµµ¿¡ ¾à¹°À» ³Ö´Â ½ÄÀÇ) Áý´Ü Åõ¾à
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á